Navigation Links
Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation

- New IVIS Kinetic System Extends Application Breadth of Market-Leading

IVIS Instrument Family -

- Imaging Products Continue to Drive Revenue Growth -

HOPKINTON, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS(R) Kinetic preclinical in vivo imaging system. The system enables researchers to non-invasively view biological events at the molecular level as they occur in real-time. The IVIS Kinetic system utilizes the latest developments in ultra-high sensitivity scientific cameras to add video capability to the company's existing line of preclinical, high sensitivity bioluminescence and fluorescence molecular optical imaging offerings. This additional capability will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted using in vivo imaging.

With the launch of the IVIS Kinetic system, researchers are now able to visualize, track, quantify and understand biological processes in real time-as the action happens-driving visual exploration and analysis of gene expression, cellular pathways and drug response. The IVIS Kinetic system features an isolation chamber that allows users to monitor conscious mice freely walking and performing tasks. By capturing images and live video, at the molecular level, researchers can witness dynamic processes and reactions, enhancing the understanding of a drug candidate's potential performance in clinical studies. Specifically, by allowing researchers to view the real-time distribution of drugs and an animal model's responses to a compound, a more thorough understanding of a drug's potential can be assessed.

"The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen," said Kevin Hrusovsky, president and chief executive officer, Caliper Life Sciences. "This system is another great example of how Caliper Life Sciences is helping pharma and biotech companies understand complex biological processes to accelerate the discovery of successful drug candidates."

Caliper's IVIS imaging systems have played a significant role in demonstrating the efficacy of various drugs, including Sutent(R) (Pfizer), Sprycel(R) (dasatinib) (Bristol-Myers Squibb), Tasigna(R) (Novartis), and Cubicin(R) (Cubist Pharmaceuticals).

Caliper offers a broad portfolio of imaging systems. For additional information or to order the IVIS Kinetic, please visit:

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit

Caliper and IVIS are registered trademarks of Caliper Life Sciences, Inc. Sutent is a registered trademark of Pfizer, Inc. Sprycel(R) is a registered trademark of Bristol-Myers Squibb. Tasigna is a registered trademark of Novartis. Cubicin is a registered trademark of Cubist Pharmaceuticals.

SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Caliper Life Sciences Presentation at UBS Global Life Sciences Conference to be Webcast
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
7. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
10. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
11. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Culprits beware, a University ... professor Jan Halámek, is taking crime scene fingerprint ...   -->   ... --> --> Halámek ... discovered a straightforward concept for identifying whether a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and ... The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately ... several North American tour dates. The Exhibition is based on Universal Pictures’ Jurassic ...
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... to adding an additional independent director, and the Company ... investigation of allegations in a recent anonymous internet report ... on both initiatives. Linda Powers stated, ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
Breaking Biology News(10 mins):